GeneDx Financial Statements
NASDAQ: WGSHealth CareMedical/Nursing ServicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GeneDx revenue and earnings
In fiscal 2025, GeneDx generated $427.5 million in revenue, up 40.0% from fiscal 2024, its 2nd consecutive year of revenue growth. GeneDx reported a net loss of $21.0 million, compared with a loss of $52.3 million a year earlier. Gross margin was 69.7% (up from 63.6%) and operating margin -3.1%.
Diluted earnings per share came in at -$0.73. Over the last 5 fiscal years, WGS's revenue has grown at a 19.0% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
GeneDx income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 427.54M | 305.45M | 202.57M | 234.69M | 212.19M | 179.32M | 196.17M |
| Revenue growth (YoY) | +39.97% | +50.79% | -13.69% | +10.60% | +18.33% | -8.59% | — |
| Cost of Revenue | 129.37M | 111.05M | 112.56M | 261.44M | 228.80M | 175.30M | 113.39M |
| Gross Profit | 298.17M | 194.40M | 90.01M | -26.75M | -16.60M | 4.03M | 82.78M |
| Operating Expenses | 311.25M | 217.61M | 270.60M | 640.90M | 429.55M | 246.02M | 113.20M |
| Research & Development | 72.03M | 45.72M | 58.27M | 86.20M | 105.16M | 72.70M | 34.91M |
| Selling, General & Admin | 239.22M | 171.89M | 199.98M | 338.24M | 318.73M | 163.93M | 68.84M |
| Operating Income | -13.08M | -23.21M | -180.60M | -667.65M | -446.15M | -241.99M | -30.41M |
| Interest Expense | — | — | — | 3.21M | 2.83M | 2.47M | 783.00K |
| Other Income (Expense) | -8.06M | -29.42M | 3.90M | 69.62M | 200.76M | 654.00K | 709.00K |
| Pretax Income | -21.14M | -52.63M | -176.69M | -598.03M | -245.39M | -241.34M | -29.70M |
| Income Tax | -116.00K | -343.00K | -926.00K | -49.05M | 0 | 0 | 0 |
| Net Income | -21.02M | -52.29M | -175.77M | -548.98M | -245.39M | -241.34M | -29.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | -0.73 | -1.94 | -7.23 | -53.63 | -2.27 | -47,036.00 | -264,056.00 |
| EPS (Diluted) | -0.73 | -1.94 | -7.23 | -53.63 | -2.27 | -47,036.00 | -264,056.00 |
| Shares Outstanding (Basic) | 28.64M | 26.89M | 24.31M | 10.24M | 108.08M | 5.13K | 124 |
| Shares Outstanding (Diluted) | 28.64M | 26.89M | 24.31M | 10.24M | 108.08M | 5.13K | 124 |
| EBITDA | -3.48M | -15.31M | -160.90M | -617.65M | -424.34M | -230.26M | -24.01M |
| Gross Margin | 69.74% | 63.64% | 44.43% | -11.40% | -7.82% | 2.25% | 42.20% |
| Operating Margin | -3.06% | -7.60% | -89.15% | -284.48% | -210.25% | -134.95% | -15.50% |
| Net Margin | -4.92% | -17.12% | -86.77% | -233.91% | -115.64% | -134.58% | -15.14% |
This table shows 7 annual periods of GeneDx's income statement, from FY 2025 back to FY 2019, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow WGS's reporting calendar. What is a income statement?